|
Volumn 63, Issue 12, 2014, Pages 1228-1229
|
Should we forget about low-density lipoprotein cholesterol?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
LOW DENSITY LIPOPROTEIN;
ATHEROSCLEROSIS;
BLOOD ANALYSIS;
CARDIOVASCULAR RISK;
CLINICAL EFFECTIVENESS;
DISEASE ASSOCIATION;
DRUG EFFICACY;
HEALTH CARE ORGANIZATION;
HUMAN;
HYPOCHOLESTEROLEMIA;
LETTER;
MEDICAL SOCIETY;
ORGANIZATIONAL DOWNSIZING;
ORGANIZATIONAL EFFICIENCY;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
RISK REDUCTION;
ADULT;
CARDIOVASCULAR DISEASE;
DIABETIC PATIENT;
DRUG DESIGN;
DRUG INDICATION;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG TARGETING;
HYPERCHOLESTEROLEMIA;
LIPOPROTEIN BLOOD LEVEL;
ONSET AGE;
ADULT;
CHOLESTEROL, LDL;
CORONARY ARTERY DISEASE;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERLIPIDEMIAS;
PRACTICE GUIDELINES AS TOPIC;
SOCIETIES, MEDICAL;
|
EID: 84896949897
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2013.11.054 Document Type: Letter |
Times cited : (14)
|
References (5)
|